ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 2635 • ACR Convergence 2024

    Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes

    Swetha Ann Alexander1, Shaobo Pei2, Gopi Penmetsa3, Soumya Reddy4, Jose Scher5, Alexis Ogdie6 and Jessica A Walsh7, 1University of Utah, Salt lake City, UT, 2University of Utah, Thousand Oaks, CA, 3University Of Utah Hospital, Salt Lake City, UT, 4NYU Grossman School of Medicine, New York, NY, 5New York University School of Medicine, New York, NY, 6Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 7Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT

    Background/Purpose: Diagnostic delays in psoriatic arthritis (PsA) among psoriasis patients are common due to under recognition by referring providers. Previous studies show that a PsA…
  • Abstract Number: 0070 • ACR Convergence 2024

    Shared and Unique Fecal and Plasma Metabolic Signatures and Increased Inflammatory Markers in Ankylosing Spondylitis, Psoriatic Arthritis and Acute Anterior Uveitis

    Sneha Couvillion1, Javier Flores1, Sean Davin2, Kimberly Ogle2, Emma Fale-Olsen2, John Davis2, Gina Many1, Carley Shaut2, Tammy Martin2, Eric Suhler2, Atul Deodhar3, James Rosenbaum4, Ernesto Nakayasu1 and Tejpal Gill2, 1PNNL, Richland, WA, 2OHSU, Portland, OR, 3Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 4Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR

    Background/Purpose: Spondyloarthritis (SpA) is a group of immune-mediated inflammatory disorders such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), along with acute anterior uveitis (AAU)…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 0591 • ACR Convergence 2024

    Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies

    Jessica A Walsh1, Joseph F. Merola2, Christopher T Ritchlin3, Yoshiya Tanaka4, Ennio Giulio Favalli5, Dennis McGonagle6, Diamant Thaçi7, Barbara Ink8, Rajan Bajracharya8, Jason Coarse9 and William Tillett10, 1Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 2UT Southwestern Medical Center, Dallas, TX, 3Allergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, 4Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 5ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, 6National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, 7Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, 8UCB Pharma, Slough, United Kingdom, 9UCB Pharma, Morrisville, NC, 10Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom

    Background/Purpose: PsA is a chronic disease, and patients (pts) can experience loss of response with sustained therapy; therefore, assessing long-term maintenance of response in pts…
  • Abstract Number: 1011 • ACR Convergence 2024

    Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster

    Jeffrey Curtis1, Danielle M Conrad2, Whitney S Krueger2, Andrew P Gara2 and Kevin Winthrop3, 1FASTER Medicine, Hoover, AL, 2AbbVie, North Chicago, IL, 3School of Medicine, Oregon Health and Science University, Portland, OR

    Background/Purpose: The risk of herpes zoster (HZ) is increased in patients with inflammatory arthritis (IA); although the Shingrix vaccine has been available since 2017, its…
  • Abstract Number: 1433 • ACR Convergence 2024

    Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients

    Andre Lucas Ribeiro1, Sydney Thib2, Kangping Cui3, Sahil Koppikar4 and Lihi Eder5, 1Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, 2Women's College Research Institute, Toronto, Canada, 3Sunnybrook Hospital, Toronto, Gravenhurst, ON, Canada, 4Women's College Hospital & University of Toronto, Toronto, ON, Canada, 5University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Ultrasound (US) is a valuable tool for enhancing disease activity assessment in psoriatic arthritis (PsA) by providing detailed visualization of both inflammatory and structural…
  • Abstract Number: 1470 • ACR Convergence 2024

    Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement

    Alen Zabotti1, Alexis Ogdie2, Masato Okada3, Rebecca Bolce4, Jeffrey Lisse5, Marcus Ngantcha5, mohamed taher5, Khai Jing Ng6 and Dennis McGonagle7, 1Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3St. Luke's International Hospital, Tokyo, Japan, 4Eli Lilly and Company, Cincinnati, OH, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lilly and Company, Madrid, Spain, 7National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom

    Background/Purpose: Nails are a challenging body area to treat in patients (pts) with psoriatic arthritis (PsA)1. Previous research found that nail psoriasis is closely related…
  • Abstract Number: 1924 • ACR Convergence 2024

    Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials

    Dania Kaur1, Fizza Zulfiqar2, Akshee Batra3 and Abhinav Vyas4, 1North Alabama Medical Center, Muscle Shoals, AL, 2Trinity Health Oakland/Wayne State University, Pontiac, MI, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Nahville, TN

    Background/Purpose: To develop effective novel treatment strategies for psoriatic arthritis that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
  • Abstract Number: 2318 • ACR Convergence 2024

    Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?

    Fadi Kharouf1, Pankti Mehta2, Shangyi Gao2, Daniel Pereira3, Richard Cook4, Dafna Gladman5 and Vinod Chandran6, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4University of Waterloo, Waterloo, Canada, 5University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriasis typically precedes psoriatic arthritis (PsA), with a variable transition period. In this study, we aimed to explore whether the time interval between the…
  • Abstract Number: 2335 • ACR Convergence 2024

    Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study

    Birte Coppers1, Sara Bayat2, Koray Tascilar1, Daniela Bohr1, Larissa Valor1, David Simon3, Filippo Fagni1, Giulia Corte2, Axel Hueber4, Harriet Morf1, verena schönau1, Michael Sticherling5, eva manger1, sonja liehr1, Juergen Rech1, Georg Schett6, Arnd Kleyer7 and Anna-Maria Liphardt1, and Birte Coppers and Sara Bayat, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 3Charité - Universittsmedizin Berlin, Berlin, Germany, 4Klinikum Nuernberg, Nuernberg, Germany, 5FAU Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, Erlangen, Germany, 6Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 7Charité - Universittsmedizin Berlin, Erlangen, Germany

    Background/Purpose: Patients with skin psoriasis (Pso) have an increased risk of developing psoriatic arthritis (PsA) (6-42%) compared to the general population (0.02-0.42%) [1]. Early diagnosis…
  • Abstract Number: 2356 • ACR Convergence 2024

    Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US

    KURT OELKE1, Emily Edson Heredia2, Sarah Ross2, Jeffrey Lisse2, Jennifer Pustizzi2, Ali Sheikhi Mehrabadi2, Natalia Bello2, Frederick Murphy3, Shikha Singla4 and Siba Raychaudhuri5, 1Rheumatic Disease Center, Glendale, WI, 2Eli Lilly and Company, Indianapolis, IN, 3Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 4Medical College of Wisconsin, Milwaukee, WI, 5UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA

    Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated efficacy in treating psoriatic arthritis (PsA) in Phase 3/4 clinical trials…
  • Abstract Number: 2636 • ACR Convergence 2024

    Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)

    Stephen Pennington1, Ruoyi Zhou2, Jonathan Brady2, Bruna Wundervald2, Andrew Parnell3, Ciarán Duffy2, Robert Perryman2, James Waddington4, Neil McHugh5, Deepak Jadon6, David Simon7, Filippo Fagni8, Georg Schett9, Fraser Morton10, Aurelie Najm10, Stefan Siebert11, Laura Coates12 and Oliver FitzGerald13, 1UCD, Dublin, Dublin, Ireland, 2Atturos, DUBLIN, Dublin, Ireland, 3NUIM, Maynooth, Ireland, 4Agilent, Manchester, United Kingdom, 5University of Bath, Bath, United Kingdom, 6Cambridge University, Cambridge, United Kingdom, 7Charité - Universittsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 9Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 10University of Glasgow, Glasgow, United Kingdom, 11School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 12University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 13UCD, Dublin 6, Dublin, Ireland

    Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
  • Abstract Number: 0074 • ACR Convergence 2024

    Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Angel Rangel-Garcia1, Marissa Krantz3, Delaney Martino1, Marc Nuzzo1 and Christopher Ritchlin4, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3University of Rochester, Rochester, NY, 4Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

    Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
  • Abstract Number: 0384 • ACR Convergence 2024

    Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study

    Corey J. Bishop1, Edwin Lam2, Sophia G. Liva3, Jocelyn H. Leu2, Amy S. Paller4, Lucia Z. Diaz5, Laura Wine Lee6, Cory Rubin7, Ruy Carrasco8, Lisa Imundo9, Azadeh Majlessi10, Katherine Berezny1, Kathleen G. Lomax1, Valerie Smith1, Renping Zhang1 and hermine brunner11, 1Janssen Research & Development, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 4Northwestern University, Feinberg School of Medicine, Chicago, IL, 5Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, 6Medical University of South Carolina, Charleston, SC, 7Michigan Dermatology Institute, Waterford, MI, 8Pediatric Rheumatology Consultants of Austin, Austin, TX, 9Columbia University Medical Center, New York, NY, 10Newport Huntington Medical Group, Huntington Beach, CA, 11Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
  • Abstract Number: 0593 • ACR Convergence 2024

    Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast

    Alvin F. Wells1, Arthur Kavanaugh2, William Tillett3, Philip S. Helliwell4, Marijn Vis5, Yuri Klyachkin6, Cynthia Deignan7, Lichen Teng7, Rebecca Wang7 and Alexis Ogdie8, 1Rheumatology and Immunotherapy Center, Franklin, WI, 2University of California San Diego, La Jolla, CA, 3Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, 5Erasmus MC, Rotterdam, Netherlands, 6Amgen, Lexington, KY, 7Amgen Inc., Thousand Oaks, CA, 8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology